Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin and spironolactone after aortic valve replacement for severe aortic stenosis
ISRCTN15612522Phase 2Not yet recruiting
- Sponsor
- University College London
- Start
- Dec 2026
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
01
Overview
Phase 2, randomised, open-label trial of dapagliflozin, spironolactone and eplerenone in aortic stenosis (AS) (4 arms), sponsored by University College London. Primary endpoint: Left ventricular mass index. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
dapagliflozinspironolactoneeplerenone
03
Conditions
aortic stenosis (AS)
Beyond the preview
Go deeper on ISRCTN15612522.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN15612522.